Suven Life Sciences Ltd, a drug discovery and development company has received permission from Drug Controller General of India (DCGI) to conduct phase-I clinical trials of SUVN-502, a potent, safe, highly selective, brain penetrant and orally active antagonist at a non-peripheral, CNS receptor site 5-HT6, intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like attention deficient hyperactivity, Parkinson, Schizophrenia.
The details can be read here.
No comments:
Post a Comment